Clinical Observation of Biyuan Tongqiao Granules Combined with Moxibustion in the Treatment of Allergic Rhinitis of Lung Qi Deficiency and Cold Type
10.13359/j.cnki.gzxbtcm.2025.05.015
- VernacularTitle:鼻渊通窍颗粒联合灸法治疗肺气虚寒型过敏性鼻炎的临床观察
- Author:
Jian WEI
1
;
Qin LI
;
Bin HAN
Author Information
1. 青岛大学医学部,山东 青岛 266971;临沂市人民医院耳鼻喉科,山东 临沂 276900
- Keywords:
Biyuan Tongqiao Granules;
moxibustion;
allergic rhinitis;
lung qi deficiency and cold type;
Treg/Th17;
inflammatory factors;
clinical observation
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(5):1140-1146
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Biyuan Tongqiao Granules combined with moxibustion in the treatment of allergic rhinitis(AR)of lung qi deficiency and cold type,and to explore its possible mechanism of action.Methods A total of 138 patients diagnosed with AR in the otolaryngology outpatient and inpatient departments of Linyi People's Hospital from November 2020 to November 2022 were selected as the study subjects.The patients were randomly divided into an observation group and a control group using a random number table,with 69 cases in each group.The control group was treated with Mometasone Furoate Nasal Spray,while the observation group received Biyuan Tongqiao Granules combined with moxibustion in addition to the control group's treatment.Both groups were treated for 4 weeks.After the ending of treatment,the clinical efficacy of the two groups was evaluated.Changes in traditional Chinese medicine(TCM)syndrome scores,serum levels of interleukin-6(IL-6),interleukin-8(IL-8),and C-reactive protein(CRP)were observed.The proportions of Treg cells and Th17 cells were compared before and after treatment,and the Treg/Th17 ratio,as well as levels of transforming growth factor β1(TGF-β1)and interleukin-17(IL-17)were calculated.The safety and incidence of adverse reactions in the two groups were evaluated.Six months after the end of treatment,the recurrence rate of patients was followed up and compared between the two groups.Results(1)After treatment,the TCM syndrome scores of both groups were significantly improved(P＜0.05),and the observation group showed significantly better improvement in TCM syndrome scores compared to the control group,with a statistically significant difference(P＜0.05).(2)After treatment,the serum levels of IL-6,CRP,and IL-8 in both groups were significantly improved(P＜0.05),and the observation group showed significantly better improvement in serum IL-6,CRP,and IL-8 levels compared to the control group,with a statistically significant difference(P＜0.05).(3)After treatment,the levels of Treg,Th17,Treg/Th17,TGF-β1,and IL-17 in both groups were significantly improved(P＜0.05),and the observation group showed significantly better improvement in these levels compared to the control group,with a statistically significant difference(P＜0.05).(4)The total effective rate in the observation group was 97.10%(67/69),while it was 76.81%(53/69)in the control group.The efficacy of the observation group was superior to that of the control group,with a statistically significant difference(P＜0.05).(5)At the 6-month follow-up,the recurrence rate in the observation group was 5.80%(4/69),while it was 24.64%(17/69)in the control group.The recurrence rate in the observation group was lower than that in the control group,with a statistically significant difference(P＜0.05).(6)There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Biyuan Tongqiao Granules combined with moxibustion in the treatment of AR of lung qi deficiency and cold type can significantly improve patients'clinical symptoms,help regulate the Treg/Th17 immune imbalance,improve inflammatory factor levels,and has a low recurrence rate,good safety,and significant efficacy.
